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PURWSE: Elevated cholesterol levels are a major 
risk factor for coronary heart disease, which 
remains a significant problem in patients beyond 
age 65 years. Because drug therapy for the 
control of hypercholesterolemia in elderly 
patients is frequently considered to be indicated, 
we investigated the efficacy and safety of 
pravastatin in the treatment of elderly subjects 
with primary hypercholesterolemia. 
PATIENTS AND METHODS: In this 96-week, 
multicenter, double-blind, placebo-controlled 
study, 142 subjects (95 women, 47 men) 64 to 
90 years of age with elevated cholesterol levels 
despite dietary intervention were randomized to 
receive pravastatin 20 mg at bedtime or 
matching placebo (2:l). Dosage could be 
doubled after 8 weeks, a bile acid-binding resin 
could be added after 16 weeks, and nicotinic 
acid or probucol could be added after 32 weeks, 
as needed, to adequately lower the low-density 
lipoprotein cholesterol (LDL-C) levels. 
RESULTS: Significant reductions in the levels of 
LDL-C (-30.9%), total cholesterol (Total-C; 
-21.9%), and triglycerides (TG; -16.7%) and 
significant increases in the levels of high-density 
lipoprotein cholesterol (HDL-C; 11.3%) were 
noted in the group receiving pravastatin 
treatment at 16 weeks (P <O.OOl compared with 
baseline, P 10.01 compared with placebo). The 
cholesterol-lowering effects of pravastatin were 
sustained throughout the 96 weeks of the trial. 
Pravastatin was well tolerated, with an overall 
incidence of adverse events nearly identical to 
that of placebo. 
CONCLUSIONS: In this study, pravastatin was well 
tolerated and effective in lowering LDL-C, Total- 
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C, and TG and in raising HDL-C during long-term 
treatment of elderly patients with primary 
hypercholesterolemia. 
T he complications of atherosclerosis, including coronary heart disease (CHD), are the leading 
cause of death in most developed nations. Elevated 
low-density lipoprotein (LDLC) and total choles- 
terol (Total-C) levels, as well as low levels of high- 
density lipoprotein cholesterol (HDLC), are directly 
related to atherogenesis and are major risk factors 
for CHD. 1-4 The prevalence of hypercholesterolemia 
and frequency of CHD increase with age, and the 
correlation between elevated lipid levels and CHD 
appears to persist after age 6S516 A clear relationship 
between lowering cholesterol levels and a reduction 
in cardiovascular morbidity and mortality in elderly 
patients with hypercholesterolemia has yet to be af- 
firmed in controlled studies, and the overall benefit 
of lipid-lowering therapy in this population has not 
yet been determined. Maintaining a balanced, fat- 
restricted diet can be difficult in the elderly, and in- 
convenient dosage forms and unpleasant side effects 
have long hindered compliance with previously 
available lipid-lowering drugs in this population. The 
3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) 
reductase inhibitors, with once-daily dosing and im- 
proved safety profiles, offer the potential for greater 
patient compliance and a more favorable balance of 
the risk of adverse effects versus the expected ben- 
efits of therapy. 
Pravastatin, a hydrophilic HMG CoA reductase in- 
hibitor, has been shown to be effective and well tol- 
erated in extensive clinical trials involving more than 
27,000 hypercholesterolemic subjects, including 
more than 15,000 taking the drug, some for up to 7 
years or more. 79 By inhibiting cholesterol synthesis 
in the hepatocyte, increasing LDL receptor activity 
and number, and facilitating LDL uptake,lO-l2 pravas- 
tatin produces dose-related reductions of up to 30% 
to 34% in levels of LDLC, 22% to 27% in levels of 
Total-C, and 10% to 25% in levels of triglycerides (TG) 
and increases of 4% to 12% in the levels of HDL 
C.718J3J4 In comparative studies in primarily middle- 
aged subjects, pravastatin has proved an acceptable 
alternative to nicotinic acid,15 probucol,16 fibric acid 
derivatives,17-lg and bile-acid sequestrants.20 The goal 
of the present study was to evaluate the use of 
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pravastatin in the long-term treatment of elderly sub- 
jects with primary hypercholesterolemia. 
PATIENTS AND METHODS 
Subject Selection 
Eligible subjects were men and women 65 years of 
age or older with primary (Type II) hypercholes- 
terolemia. Potential subjects with elevated cholesterol 
levels were identified in medical clinics at the partic- 
ipating institutions and referred to a dietitian for coun- 
seling. After at least 6 weeks on a low-fat, low-cho- 
lesterol diet, the mean of two consecutive 
determinations of fasting plasma LDLC concentration 
was required to be greater than the 95th percentile for 
the corresponding age and gender group of the US 
population21 (165 mg/dL for men or above 170 mgdL 
for women), and the mean TG concentration in the 
same specimens was to be less than 250 mg/dL. 
Subjects with homozygous familial hypercholes- 
terolemia, Type I, III, IV, or V hyperlipoproteinemia, 
or significant endocrine, renal, hepatic, metabolic, or 
cardiovascular disease were excluded, as were those 
taking medication (eg, corticosteroids, thiazide di- 
uretics, beta-adrenergic blockers) that might affect 
lipid levels. Women receiving a stable dose of conju- 
gated estrogens were eligible. Subjects were required 
to give informed written consent both at the beginning 
of the initial 4%week study and the 48week extension 
phase. The protocol was approved by the institutional 
review boards of the three study centers. 
Study Design 
This clinical trial was a randomized, double-blind, 
parallel, placebo-controlled examination of the eff- 
cacy and safety of pravastatin in elderly subjects with 
primary hypercholesterolemia inadequately respon- 
sive to dietary intervention. With counseling by dieti- 
tians, a low-fat, low-cholesterol, eucaloric diet, equiv- 
alent to the American Heart Association Phase I, was 
started 6 weeks or more before blood was drawn for 
the qualifying lipid evaluations. This diet was contin- 
ued throughout the trial and periodically evaluated at 
clinic visits by means of a 3day food record. Subjects 
were instructed not to otherwise change their life- 
styles (eg, start an exercise program) during the study. 
Any lipid-lowering medications were discontinued at 
least 9 weeks before randomization. After a dietary 
stabilization period of 7 to 14 weeks, subjects who 
qualified were randomly assigned to one of two treat- 
ment groups, pravastatin 20 mg at bedtime or placebo, 
in a 2:l ratio. The short-term treatment phase was 16 
weeks in duration. After completing the initial 8 
weeks, a treatment decision was made for all subjects 
dependent upon their week 8 LDLC results, with 
blinded therapy increased from 20 mg at bedtime to 
40 mg at bedtime if the subject’s LDLC concentration 
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was still above the 95th percentile. After 16 weeks of 
double-blind therapy in the short-term phase, if the 
LDLC concentration remained above the 75th per- 
centile, a bile acid-binding resin could be added to the 
regimen of subjects in either treatment group at the 
beginning of the long-term phase of the study. Later, 
in the long-term phase, nicotinic acid or probucol 
could be added as needed to attempt to reduce LDL 
C levels below the 75th percentile. The initial 48-week 
study was followed by a 48-week extension period, 
with the treatment regimen to remain as it was in the 
fmal 16 weeks of the first year. 
Clinical Safety and Laboratory Evaluation 
Subjects returned to the clinic at 2- to 6-week in- 
tervals throughout the trial. Health status, interim ill- 
nesses, and the use of non-study drugs were evaluated 
and recorded at each clinic visit. Comprehensive phys- 
ical examinations, clinical tests, and dietary compli- 
ance evaluations were performed at specified inter- 
vals. Clinical adverse events, defined as any new or 
worsening illnesses, signs, or symptoms, and compli- 
ance with study drug, as determined by counting the 
remaining supply of tablets, were assessed at each 
clinic visit. 
Lipid analyses were performed by the Lipid 
Research Laboratory, Sinai Hospital of Detroit, which 
is certified by the Centers for Disease Control/ National 
Heart, Lung and Blood Institute Standardization 
Program. Concentrations of Total-C and TG were de- 
termined using standard enzymatic procedures. Levels 
of HDLC were determined after precipitation of 
apolipoprotein B containing lipoproteins with dextran 
sulfate-MgCl,. The LDLC values were calculated using 
a variation of the F’riedewald formula described by 
Delong: LDLC = Total-C - (0.16TG + HDLC).22 
Baseline clinical safety assessments, including a 
complete medical history, a physical examination, a 12- 
lead electrocardiogram, a complete ophthalmologic 
examination (including slit-lamp examination and lens 
opacity grading), and a chest roentgenogram (if a film 
taken in the previous 3 months was not on file), were 
completed within the dietary stabilization/lead-in pe- 
riod. Laboratory safety tests included hematology 
(complete blood count, including differential), clinical 
chemistry, and urinalysis on a freshly voided morning 
specimen (with microscopic examination of the sedi- 
ment if the dipstick results were positive for blood or 
white blood cells) at each clinic visit; serum thyroxine 
(TJ determination at baseline and at weeks 16 and 48; 
and a stool test for occult blood at baseline and at 
weeks 8, 16, and 48. The laboratory tests were per- 
formed by SmithKline Beecham Clinical Laboratories 
(Van Nuys, CA) employing quality assurance proce- 
dures in accordance with standards required by the US 
government agencies licensing clinical laboratories. 
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Statistical Analysis 
The two treatment groups were compared for ho- 
mogeneity of baseline measures. Efficacy parameters 
were analyzed after logarithmic transformations re- 
sulting in normality and homogeneity of variance. 
Model assumptions were assessed by Shapiro-WilkW- 
test and Levene’s test. Analyses of covariance were 
performed on the natural logarithms of the follow-up 
visit value and the baseline value with treatment and 
investigator as model effects and logarithmic value of 
baseline measure as a covariate. The statistical sig- 
nificance tests were performed for between- and 
within-group comparisons, and P-values were deter- 
mined for short-term visits only. For the long-term pe- 
riod, only within-group comparisons were made, and 
95% confidence limits without P-values were reported. 
Within-group changes from baseline were assessed 
through a paired t-statistic using the least squares 
means and mean squared error from the linear model 
above. The 95% confidence limits for the mean per- 
cent changes, adjusted for baseline differences and 
numerical imbalances among investigators, were ob- 
tained by exponentiating their upper and lower con- 
fidence limits in the logarithmic scale. The results of 
the analyses were summarized by arithmetic means, 
standard deviations, and adjusted percent changes 
from baseline with 95% confidence limits. 
RESULTS 
A total of 142 patients were randomized. All 142 pa- 
tients received study medication and were included 
in the safety database; however, 1 patient discontm- 
ued prior to any efficacy data being obtained in the 
TABLE I 
Baseline Demographic Characteristics 
of the Intent-to-Treat Population 
Treatment Group 
Pravastatin Placebo Total 
Variable (n = 93) (n q 48) (n q 141) 
Sex 
Male 33 (35%) 14 (29%) 47 (33%) 
Female 60 (65%) 34 (71%) 94 (67%) 
Age (years) 
Mean 70.3 70.8 70.5 
SD 4.8 5.7 5.1 
Range 64-86 65-90 64-90 
Race 
White 73 (78%) 33 (69%) 106 (75%) 
Black 20 (22%) 14 (29%) 34 (24%) 
Oriental 0 (0.0%) 1 (2.1%) 1 (0.7%) 
Lipids (mg/dL) 
LDL-C 199.0 207.9 202.0 
Total-C 272.2 278.7 274.4 
HDL-C’ 50.4 45.9 48.9 
TG 142.6 155.5 147.0 
’ Significant difference between treatment groups at baseline (P <0.05). 
LDL-C = low-density lipoprotein cholesterol; Total-C = total cholesterol; 
HDL-C = high-density lipoprotein cholesterol; TG = triglycerides. 
active-treatment phase, leaving 141 subjects in the in- 
tent-to-treat population (all randomized subjects who 
had at least one follow-up visit with efficacy deter- 
mination). Of the 141 patients, 136 completed the first 
16 weeks of the study, 114 completed the next 32 
weeks, and 96 completed 96 weeks. 
As shown in Table I, the intent-to-treat population 
included more women (94, or 67%) than men (47, or 
330/o)), had an overall mean age of 70.5 years, and was 
TABLE II 
Effect of Treatment on Lipid Values at Week 16 
Lipid/ Baseline (mg/dL) Week 16 (mg/dL) 
Treatment’ Mean (SD) Mean (SD) 
LDL-C 
Pravastatin 198.4 (23.6) 138.7 (24.4) 
Placebo 208.4 (40.8) 209.8 (49.0) 
Total-C 
Pravastatin 271.6 (28.2) 213.6 (31.1) 
Placebo 279.2 (42.8) 281.9 (49.3) 
HDL-C 
Pravastatin 50.2 (12.6) 55.4 (14.2) 
Placebo 46.0 (10.6) 47.7 (9.1) 
TG 
Pravastatin 144.1 (41.5) 121.8 (39.1) 
Placebo 154.5 (46.1) 152.2 (70.0) 
* N=90 for the pravastatin-treatment group; N = 47 for the placebo-treatment group. 
t Adjusted for pretreatment differences and numerical imbalances among investigators. 
t P _<O.OOl versus baseline and placebo. 
5 P ~0.001 versus baseline and P <O.Ol versus placebo. 
1 P ~0.05 versus baseline. 
SD = standard deviation; CL = confidence limits; LDL-C = low-density lipoprotein cholesterol; Total-C = total cholesterol; 
HDL-C = high-density lipoprotein cholesterol; TG = triglycerides. 
% Change+ 
Mean (95% CL) 
-30.9x (-33.1, -28.7) 
0.6 (-3.7, 5.17) 
-21.9% (-23.7, -20.0) 
0.9 (-2.3, 4.25) 
11.35 (8.5, 14.2) 
3.61 (0.1, 7.2) 
-16.75 (-21.1, -12.1) 
-4.2 (-11.1, 3.2) 
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density lipoprotein cholesterol; HDLcholesterol 
= highdensity lipoprotein cholesterol. 
predominantly white (75%). The median age of the 
study population was determined to be 69 years. With 
the exception of baseline HDLC values, no signifi- 
cant differences in the demographic characteristics 
between the two treatment groups were detected by 
a &i-square test of association or a linear model ad- 
justed for numerical differences among investigators. 
Efficacy Analyses 
The primary efficacy criterion was the reduction at 
week 16 in fasting plasma LDLC levels from the base- 
line value. Changes in levels of Total-C, HDLC, and 
TG were secondary efficacy criteria After week 16, 
all subjects were eligible to be treated with additional 
lipid-lowering therapy. The average daily dose of 
pravastatin in the active-treatment group at week 16 
was 20.4 mg, with only 1 of 88 patients in the pravas- 
tatin treatment group having the dose increased after 
the measurement of LDLC at week 8. 
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Lipid and Lipoprotein Response 
The mean percentage changes in adjusted mean 
lipid values from baseline at week 16 are presented in 
Table II. The F’igure plots the percentage changes in 
these parameters throughout the short-term phase. 
Statistically significant decreases in LDLC and 
Total-C were noted in the pravastatin-treatment group 
after 4 weeks of therapy (P 10.001 compared with 
baseline and placebo). These effects were sustained 
and remained significant at all timepoints for the du- 
ration of the N-week pravastatin-placebo comparison 
period (P 10.001 compared with baseline and 
placebo). Mean percent elevations of HDLC levels 
and mean percent reductions in TG values with 
pravastatin therapy were significantly different from 
baseline and placebo at all timepoints in the first 16 
weeks (P 10.05 to 0.001). At week 96, the group orig- 
inally assigned pravastatin had reductions in levels of 
LDLC of 29.9%, Total-C 20.2%, and TG 9.0% and ele- 
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TABLE Ill 
Most Common Adverse Events, Weeks 1 Through 16* 
Number (%) of Subjects 
Pravastatin Placebo 
Adverse Event (n=94) (n=48) 
Musculoskeletal pain 13 (13.8) 6 (12.5) 
Upper respiratory infection 11 (11.7) 7 (14.6) 
Headache 7 (7.4) 5 (10.4) 
Dizziness 9 (9.6) 2 (4.2) 
Cough 7 (7.4) 3 (6.3) 
Flatulence 6 (6.4) 4 (8.3) 
Influenza 7 (7.4) 3 (6.3) 
Abnormal urination 6 (6.4) 3 (6.3) 
Fatigue 4 (4.3) 5 (10.4) 
Insomnia 3 (3.2) 5 (10.4) 
*The events listed are the 10 most common events for both treatment 
groups, in decreasing order of frequency. 
vations of levels of HDLC by 11.6%. The correspond- 
ing 96week results for the group originally assigned 
placebo, but at this time receiving alternative therapy, 
were l&8%, 13.?%, O.l%, and 3.5%, respectively. 
Safety Results 
The evaluation of drug safety was conducted for 
the two distinct phases of the trial, the short-term 
(weeks 1 through 16) phase and the long-term (weeks 
17 through 102) phase. Safety analyses were per- 
formed on the total randomized population. Although 
the study was 96 weeks in duration, some patients 
were evaluated up to 102 weeks after randomization. 
Pravastatm was well tolerated in this study. Four 
of 142 subjects (2.8%) discontinued treatment be- 
cause of clinical adverse events during the first 16 
weeks of the study, 3 of 94 (3.2%) in the pravastatin 
group (generalized weakness, epigastric pain, and 
dizziness), and 1 of 48 (2.1%) in the placebo group 
(skin rash). The frequencies of adverse events during 
the short-term phase were 26.6% and 33.3% for the 
pravastatin- and placebo-treatment groups, respec- 
tively. The 10 most common adverse events in the 
short-term phase are shown in Table III. There were 
no statistically significant differences between treat- 
ment groups in the frequency of these 10 events. 
There was one serious cardiovascular adverse event 
reported in the short-term, a case of angina leading 
to hospitalization in a subject receiving placebo. Four 
subjects (2.8%) were withdrawn from the study dur- 
ing the first 16 weeks because of laboratory abnor- 
malities, two (2.1%) in the pravastatin group and two 
(4.2%) in the placebo group. Of the two pravastatin- 
treated subjects withdrawn, one had elevated Y-glu- 
tamyl transferase (GGT) and alkaline phosphatase 
values, and the second had proteinuria, as evidenced 
by dipstick reading. Of the two placebo-treated sub- 
jects withdrawn, one experienced elevations of ala- 
TABLE IV 
Most Common Adverse Events, Weeks 17 Through 102’ 
Number (%) of Subjects 
Pravastatin Placebo 
Adverse Event (n=89) (n=47) 
Musculoskeletal pain 29 (32.61 13 (27.7) 
Upper respiratory infection 25 (28.1) 6 (12.3) 
Constipation 4 (4.5) 14 (29.8) 
Dizziness 8 (9.0) 8 (17.0) 
Abdominal pain 7 (7.9) 8 (17.0) 
Diarrhea 8 (9.0) 7 (14.9) 
Influenza 13 (4.6) 2 (4.3) 
Nausea/vomiting 6 (6.7) 9 (19.1) 
Vision disturbance 12 (13.5) 3 (6.4) 
Pharyngitis 11 (12.4) 2 (4.3) 
*The events listed are the 10 most common events for both treatment 
groups, in decreasing order of frequency. 
nine aminotransferase (ALT) and aspartate amino- 
transferase (AS’) values, and the other had illl asymp- 
tomatic decrease in white cells. 
Eighteen of 136 subjects (13.2%) 9 of 89 (10.1%) 
pravastatin-treated subjects, and 9 of 47 (19.1%) placebo- 
treated subjects, discontinued due to an adverse event 
or a marked laboratory abnormality @redefined by the 
protocol) during the Wweek long-term phase. There 
was a high frequency of adverse events in this elderly 
study population in both the pravastatin-treated group 
(96.6%) and the placebotreated group (95.7%). The in- 
creases in discontinuates and the frequency of adverse 
events in the long-term phase are to be expected in light 
of the six-fold increase in length of exposure. The 10 
most common events in the long-term phase are shown 
in Table IV. The syndrome of drug-induced myopathy 
(myalgia associated with increase in creatine kinase 
more than 10 times the upper limit of normal) was not 
observed in any pravastatin-treated subject at any time 
during the trial. There were three serious cardiovascu- 
lar adverse events involving cardiac ischemia reported 
in each treatment group during the long-term (3.4% in 
the pravastatin group and 6.4% in the placebo group). 
No statistically significant differences between treat- 
ment groups in the frequency of marked laboratory test 
abnormalities were noted in either the short-term or 
the long-term analyses. No significant changes from 
baseline or differences between groups were observed 
for mean creatine kinase values during the short-term 
phase. The pravastatin group showed statistically sig- 
nificant (P 10.05) increases in mean A§T and ALT lev- 
els in the short-term phase relative to both baseline 
and the placebo group, but these had no apparent clin- 
ical importance as they were small (0.7 to 2.4 u/L) and 
did not result in mean values outside the normal range. 
During the long-term phase, the values for creatine ki- 
nase, AST, and ALT were similar to those observed in 
the short-term period. 
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There was no difference between treatment groups 
in the overall incidence of lens opacity progression 
or in any of the individual lens parameters, except for 
cortical opacity, in which the control group experi- 
enced an unexplained improvement. 
COMMENTS 
Hypercholesterolemia remains a substantial prob- 
lem in the elderly (patients more than 65 years of age), 
with one third of older men and one half of older 
women having serum cholesterol levels greater than 
240 mg/dL?l Age is an additional risk factor for CHD, 
with the prevalence, incidence, morbidity, and mortal- 
ity of CHD increasing with advancing age.23 There are 
distinct sex-related differences. For men, CHD in- 
creases rapidly after middle age, whereas for women 
the largest increase is beyond age 65.23 Pharmacologic 
management of cholesterol abnormalities in the elderly 
using HMG CoA reductase inhibitors is becoming the 
preferred choice of treatment owing to the dependable 
efficacy and excellent tolerability of these drugs, the 
undesirable side effects of other therapeutic agents, 
and the difficulties in maintaining a balanced low-cho- 
lesterol, low-fat diet in this population.24 
Controversy remains regarding the use of pharma- 
cologic agents in the management of hypercholes- 
terolemia in the elderly, despite increasing evidence 
of the association of serum cholesterol and CHD in 
this population. Although early data from 
Framingham demonstrated no association of Total-C 
with coronary events in subjects over age 65 yearsz5 
subsequent analyses have shown a direct relationship 
of LDLC values and an inverse relationship of HDL- 
C levels to the occurrence of coronary events in the 
elderly. 26 The most recent review of the Framingham 
data on the elderly population suggested that elevated 
Total-C remains a significant risk factor in older pa- 
tients and that this relationship is stronger for women 
than for men.27 The Honolulu Heart Program, which 
studied a cohort of men of Japanese ancestry, has re- 
ported an association of coronary events with ele- 
vated serum cholesterol values in men 65 to 75 years 
of age.5 The Coronary Heart Disease in the Elderly 
Study by the Kaiser Permanente Medical Care 
Program concluded that increased serum cholesterol 
is directly associated with CHD mortality in elderly 
men.28 Finally, the trend toward decreased mortality 
from coronary disease from 1961 to 1983 has been 
shown in the elderly as well as in the younger popu- 
lations.2g Thus, although differences of opinion still 
exist, the majority of the clinical evidence at this time 
supports the premise that elevated serum cholesterol 
is an important risk factor for CHD in the elderly. 
Although the relative risk of CHD morbidity and 
mortality from hypercholesterolemia may be some- 
what lower in the elderly than in the younger popu- 
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lation, the prevalence, and therefore the attributable 
risk, is high. Denke and Grundy suggest an assess- 
ment of the relative risks and benefits as well as con- 
sideration of the individual’s overall health status and 
competing risks prior to administering cholesterol- 
lowering therapy to elderly patients.24 As concluded 
by Bilheimer, the elderly are likely to benefit from 
risk factor reduction, and decisions on treatment for 
elevated cholesterol levels should not be made sim- 
ply on the basis of age but should also consider the 
presence and severity of other diseases; the patient’s 
mental status, and his or her expectations from med- 
ical care.3o In clinical practice, the elderly patient with 
vascular disease is often very aware of the importance 
of cardiovascular risk factor control and will be 
greatly concerned about elevated cholesterol levels. 
If patients over the age of 65 years have a demon- 
strated vascular abnormality, such as coronary, 
carotid, or peripheral vascular disease, and also have 
elevated lipid levels, then strong consideration of 
pharmacologic treatment is indicated, especially if 
they are otherwise in good health. 
In this study, pravastatin was effective in signifi- 
cantly reducing the levels of LDLC, Total-C, and TG 
in elderly subjects with hypercholesterolemia 
Pravastatin was also effective in raising HDLC levels 
from baseline. These lipid effects observed with 
pravastatin treatment at an average daily dose of ap- 
proximately 20 mg are comparable to those reported 
in several other clinical trials involving primarily 
younger subjects. v Advancing age does not appear to 
have an impact on the efficacy of pravastatin. In ad- 
dition, pravastatin exhibited a high degree of safety 
tid was well tolerated during extended treatment in 
these older patients, as has previously been reported 
to be the long-term experience of the drug in younger 
patients9 In conclusion, long-term pravastatin therapy 
was successful in improving the lipid profile of this el- 
derly population without appreciable adverse effects. 
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